Hepatitis B teratitis III can be treated with oral entecavir antiviral therapy, entecavir is one of the preferred hepatitis B antiviral drugs, and the treatment course is at least four years. If one year of oral entecavir treatment results in undetectable hepatitis B DNA, normalization of aminotransferases, disappearance of E antigen, and production of E antibodies, consolidation of treatment for at least three more years is required. During this period, review every six months, has remained unchanged, can consider stopping the drug observation, prolonging the course of treatment can reduce recurrence. Regular monitoring should be done during antiviral therapy, with routine blood tests, biochemistry, hepatitis B virus DNA, liver elastography, ultrasound and alpha-fetoprotein every 3-6 months to observe the efficacy of the treatment and the occurrence of adverse reactions. Within the first three months after discontinuation of the drug, biochemistry indexes, hepatitis B penta and hepatitis B virus DNA should be tested every month, then every three months, liver ultrasound and alpha-fetoprotein every six months, and the above indexes should be tested every six months after one year.